key: cord-0915999-9sfqs4nd
authors: Di Lorenzo, Giuseppe
title: Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol. In press Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?
date: 2020-04-24
journal: Eur Urol
DOI: 10.1016/j.eururo.2020.04.030
sha: fb98375058ffe9102b2151f602bc62f04b9e927a
doc_id: 915999
cord_uid: 9sfqs4nd

nan

that treatment with oral androgen receptor signaling 23 inhibitors (ARSIs) should not be stopped and that chemo-24 therapy should be replaced with an oral ARSI during the 25 COVID-19 pandemic [2] . 26 Although it is true that chemotherapy and radiotherapy 27 lead to suppression of the immune system, thus exposing 28 patients, especially those >70 yr of age, to a greater 29 infectious risk, and most chemotherapies induce neutrope-30 nia, affecting neutrophils, the body's first line of defense, I 31 believe that a warning regarding ARSIs is also necessary for 32 the three following reasons. 

COVID-19: global consequences for oncology

Advice for medical oncology care of Please cite this article in press as: Di G. Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic